Status:
NOT_YET_RECRUITING
Dexmedetomidine and Nalbuphine as Analgesic Adjuvants to Bupivacaine in Superficial Cervical Block.
Lead Sponsor:
Kasr El Aini Hospital
Conditions:
Anterior Cervical Discectomy and Fusion (ACDF)
Eligibility:
All Genders
21-60 years
Phase:
PHASE4
Brief Summary
Anterior cervical discectomy and fusion (ACDF) nowadays is considered a common procedure.postoperative pain can hinder recovery and prolong hospital stay. The superficial cervical plexus block (SCPB) ...
Detailed Description
The aim of the current study is to evaluate whether the addition of Dexmedetomidine to bupivacaine is comparable to the addition of nalbuphine in superficial cervical plexus block in patients undergoi...
Eligibility Criteria
Inclusion
- Physical status ASA I and ASA ll.
- Both males and females
- Age 21- 60 years.
- Patients undergoing elective anterior cervical discectomy and fusion for 1 or 2 levels.
Exclusion
- Patient refusal.
- Patients undergoing anterior cervical vertebrectomy and reconstruction.
- Patients with a history of allergy to local anesthetics or any used drugs in study.
- Infection at the site of the block.
- Patients with multiple cervical spine traumas.
- Patients having surgery for malignant tumors.
- Pre-existing peripheral neuropathies.
- Pregnant female.
- Patients with uncontrolled hypertension or cardiac problems as (heart block, sick sinus syndrome and ischemic heart disease).
- Patients with coagulopathy (INR\>1.5).
- Patients with failed block.
Key Trial Info
Start Date :
July 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06490614
Start Date
July 1 2024
End Date
November 1 2024
Last Update
July 8 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.